Heather E. Laferriere

Ms. Heather E. Laferriere

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
RDRussom Desta
Russom Desta
CBCharlotte Blumrosen
Charlotte Blumrosen
Heather E. LaferriereHeather E. Laferriere
Heather E. Laferriere
ASAades Saluja
Aades Saluja
MBMarino A Bruce
Marino A Bruce
EUEbele M. Umeukeje
Ebele M. Umeukeje
Background: Black Americans have a disproportionately increased risk of diabetes, hypertension, and kidney disease, and higher associated morbidity, mortality, and hospitalization rates than their White peers. Structural racism amplifies these disparities, and negatively impacts self-care including medication adherence, critical to chronic disease management. Systematic evidence of successful interventions to improve medication adherence in Black patients with diabetes, hypertension, and kidney disease is lacking. Knowledge of the impact of therapeutic alliance, ie, the unique relationship between patients and providers, which optimizes outcomes especially for minority populations, is unclear. The role and application of behavioral theories in successful development of medication adherence interventions specific to this context also remains unclear. Objective: To evaluate the existing evidence on the salience of a therapeutic alliance in effective interventions to improve medication adherence in Black patients with diabetes, hypertension, or kidney disease. Data Sources: Medline (via PubMed), EMBASE (OvidSP), Cumulative Index of Nursing and Allied Health Literature (CINAHL) (EBSCOhost), and PsycINFO (ProQuest) databases. Review Methods: Only randomized clinical trials and pre/post intervention studies published in English between 2009 and 2022 with a proportion of Black patients greater than 25% were included. Narrative synthesis was done. Results: Eleven intervention studies met the study criteria and eight of those studies had all-Black samples. Medication adherence outcome measures were heterogenous. Five out of six studies which effectively improved medication adherence, incorporated therapeutic alliance. Seven studies informed by behavioral theories led to significant improvement in medication adherence. Discussion/Conclusion: Study findings suggest that therapeutic alliance-based interventions are effective in improving medication adherence in Black patients with diabetes and hypertension. Further research to test the efficacy of therapeutic alliance-based interventions to improve medication adherence in Black patients should ideally incorporate cultural adaptation, theoretical framework, face-to-face delivery mode, and convenient locations.

11 January 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
SDSatya Das
Satya Das
SPSharon Phillips
Sharon Phillips
CLCody L. Lee
Cody L. Lee
RARajiv Agarwal
Rajiv Agarwal
EBEmily Bergsland
Emily Bergsland
ADArvind Dasari
Arvind Dasari

27 October 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SDSatya Das
Satya Das
LDLiping Du
Liping Du
CLCody L. Lee
Cody L. Lee
NANina D. Arhin
Nina D. Arhin
JCJennifer A. Chan
Jennifer A. Chan
ADArvind Dasari
Arvind Dasari
Neuroendocrine neoplasms (NENs) are heterogenous tumors with incidence and prevalence that continue to increase steadily.1 Despite their heterogeneity, NENs have historically been grouped homogenously in clinical trials. A prior publication examining the design of therapeutic phase II and III clinical trials in patients with gastroenteropancreatic neuroendocrine tumors (NETs) identified limitations in these studies, such as the inclusion of multiple tumor types, tumors with unspecified differentiation or grade, and nonprogressive tumors.2 Over the last decade, the adoption of a more advanced pathological classification system has significantly influenced NEN categorization. In particular, the most pronounced addition to the 2019 World Health Organization pathologic classification system for NENs was the definition of the grade 3 well-differentiated NET category, which furthered the distinction between well-differentiated NETs and poorly differentiated neuroendocrine carcinomas (NECs).3,4 Also over this period of time, from 2010 to 2020, several targeted therapies (ie, everolimus and sunitinib) were licensed by national regulatory bodies and clinical trial design recommendations from the 2011 National Cancer Institute (NCI) NET Clinical Trials Planning Meeting were disseminated.5-8 Given these advances, in this analysis, we sought to assess whether there had been changes in study design, eligibility, accrual, sponsorship, and outcomes between phase II or III NEN studies that began enrollment between 2000 and 2009 vs between 2010 and 2020.

22 May 2024 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
SSShannon S. Stockton
Shannon S. Stockton
GAG. Dan Ayers
G. Dan Ayers
CLCody Lee
Cody Lee
Heather E. LaferriereHeather E. Laferriere
Heather E. Laferriere
SDSatya Das
Satya Das
JBJordan Berlin
Jordan Berlin
In the era of precision oncology (PO), systemic therapies for patients (pts) with solid tumors have shifted from chemotherapy (CT) to targeted therapy (TT) and immunotherapy (IO). This systematic survey describes features of trials enrolling between 2010 and 2020, focusing on inclusion criteria, type of dose escalation scheme (DES) utilized, and use of expansion cohorts (ECs). A literature search identified phase I studies in adults with solid tumors published January 1, 2000– December 31, 2020 from 12 journals. We included only studies enrolling between 2010 and 2020 to better capture the PO era. Two reviewers abstracted data; a third established concordance. Of 10,744 studies, 10,195 were non-topical or enrolled prior to 2010; 437 studies were included. The most common drug classes were TT (47.6%), IO (22%), and CT (6.9%). In studies which reported race, patients were predominantly white (61.7%) or Asian (25.7%), followed by black (6.5%) or other (6.1%). Heterogeneity was observed in the reporting and specification of study inclusion criteria. Only 40.1% of studies utilized ECs, and among the studies which used ECS, 46.6% were defined by genomic selection. Rule-based DES were used in 89% of trials; a 3+3 design was used in 80.5%. Of all drugs tested, 37.5% advanced to phase II, while 10.3% garnered regulatory licensure (for an indication tested in phase I). In the era of PO, TT and IO have emerged as the most studied agents in phase I trials. Rule-based DES, which are more relevant for escalating CT, are still chiefly utilized.

2 October 2021 in Medical Reference Services Quarterly
Verified
Journal Article
Open access
PWPhilip Walker
Philip Walker
Heather E. LaferriereHeather E. Laferriere
Heather E. Laferriere
Rachel Lane WaldenRachel Lane Walden
Rachel Lane Walden
CICamille Ivey
Camille Ivey
Demonstrating added value can be very challenging, yet it is becoming important in academic libraries. The current literature primarily discusses citation analysis and usage reports to demonstrate return on investment for collections or impact on scholarly activity. However, value is not only in our collections but also in the library staff who support the institutional mission. Vanderbilt University’s Annette and Irwin Eskind Family Biomedical Library and Learning Center has been experimenting with several methods to supplement the collections data with services performed by the staff. This article discusses the project’s four phases as part of the goal to strategically demonstrate the biomedical library’s added value to the university and medical center.

21 September 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
SDSatya Das
Satya Das
SPSharon Phillips
Sharon Phillips
CLCody Lebeck Lee
Cody Lebeck Lee
RARajiv Agarwal
Rajiv Agarwal
EBEmily Bergsland
Emily Bergsland
ADArvind Dasari
Arvind Dasari
Aim: Although anti-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) have been tested in patients with neuroendocrine tumors (NETs) over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population. Methods: All phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021, across major trial databases, were searched in August 2021 for relevant studies. The primary objectives of the meta-analysis were to compare objective response rate (ORR) and progression-free survival (PFS) between patients with pancreatic (p) NETs and extra-pancreatic (ep) NETs and the incidence rate ratio (IRR) of adverse events (AEs) between patients receiving anti-VEGF RTKIs and control. Results: 1611 patients were available for the meta-analysis; 1194 received anti-VEGF RTKIs. ORR in pNETs was 18% (95% CI 13-25%) while ORR in epNETs was 8% (95% CI 5-12%); test for differences between pNETs and epNETs (x12 = 8.38, p < .01). Median PFS in pNETs was 13.9 months (95% CI 11.43-16.38 months) while median PFS in epNETs was 12.71 months (95% CI 9.37-16.05 months); test for differences between pNETs and epNETs (x12 = .35, p = .55). With regards to common grade 3/4 AEs, patients who received anti-VEGF RTKIs were more likely to experience hypertension (IRR 3.04, 95% CI 1.63-5.65) and proteinuria (IRR 5.79, 95% CI 1.09-30.74) relative to those who received control. Conclusions: Anti-VEGF RTKIs demonstrate anti-tumor effect in both pNETs and epNETs, supporting their development in both populations. These agents also appear to be safe in patients with NETs.